Silo Pharma, Inc. SILO
Silo Pharma, Inc. (Nasdaq: SILO) is a CNS/neurology/psychiatry drug developer. Its lead program, SPC-15, is in Pre-clinical for PTSD and stress-induced anxiety disorders (intranasal prophylactic). Its next catalyst on record is SPC-15: IND submission (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SPC-15 — IND submission (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SPC-15 | PTSD and stress-induced anxiety disorders (intranasal 5-HT4 receptor agonist, 505(b)(2) path) | small molecule | Pre-clinical |
| SP-26 | Fibromyalgia and chronic pain (ketamine-loaded dissolvable polymer implant) | device-combination | Pre-clinical |
| SPC-14 | Alzheimer's disease (intranasal; NMDAR and 5-HT4) | small molecule | Pre-clinical |
| SPU-16 | CNS disorders, initially multiple sclerosis (CNS-homing peptide); UMB license terminated, option expired March 31, 2026 | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.